Melodiol Global Health Limited

Melodiol To Streamline Portfolio With Up To A$30M Asset Sale To Us Listed Panacea – Maintaining Significant Stake In Spin-Off Vehicle

Melodiol Global Health Limited (ASX:ME1, FRA:1X8) (‘Melodiol’ or ‘the Company’), is delighted to announce a non-binding Letter of Intent (LOI) with the US-based entity, Panacea Life Sciences Holdings, Inc. (‘Panacea’) (OTCQB: PLSH). The LOI pertains to the divestment of two of Melodiol's prominent business units, Sierra Sage Herbs, LLC ("SSH") and Halucenex Life Sciences Inc. ("Halucenex"), for an up-front aggregate consideration of approximately U$5m in cash and scrip. The LOI also includes an additional US$15m in earn-out clauses, which if met, will provide additional value to Melodiol.


Highlights:

  • Melodiol secures a non-binding LOI with Panacea Life Sciences Holdings, Inc. (‘Panacea’) (OTCQB: PLSH), a US company specialising in manufacturing, R&D, and distribution of high-quality, GMP-certified health & wellness products, for the sale of Sierra Sages Herbs, LLC (‘SSH’) and Halucenex Life Sciences Inc. (“Halucenex”) for an initial approximate US$5m in cash and scrip
  • LOI includes additional earn-out components valued at up to US$15m, which will allow Melodiol to further increase its shareholding in Panacea should conditions be met following SSH’s potential revenue growth
  • Panacea's recent operational progress includes acquisitions of eight retail locations offering VAPE and CBD products in Tampa, Florida, generating US$2.9m of annual revenues for the fiscal year ended 31 Dec 2022, and a research collaboration with Colorado State University’s Cannabinoid Research Centre (CRC)
  • Panacea, through its diverse trademark portfolio (PANA Health, PANA Beauty, PANA Sport, PANA Pet, & PANA Life), operates across the entire cannabinoid value chain and achieved significant customer growth during Q1 CY2023
  • Panacea is headquartered in Golden, Colorado where it operates a sophisticated 51,000 square foot, cGMP-certified facility
  • Melodiol's divestment of SSH and Halucenex allows for concentration on group profitability, via the substantial growth at Health House International and Mernova Medicinal Inc., with the purchase price including US$2m in cash and the balance in Panacea common stock, promising further upside potential
  • Post-transaction, Melodiol will be the largest shareholder in Panacea, enabling a strategic expansion into the US market. This aligns with the Company’s long stated objective to increase exposure to US capital markets
  • Panacea's expertise will aid in the growth of SSH and Halucenex, significantly reducing Melodiol’s cash burn, and allowing ME1 to focus on accelerating the group’s near term profitability
  • Transaction enables Panacea, a complementary US specialist business, to collaborate with SSH and Halucenex, driving growth and pursue cash flow positivity for SSH via potential synergies. Additionally, if completed, it would secure continued funding for Halucenex's progression into successful Phase II and forthcoming Phase III trials. This strategic move would also significantly decrease Melodiol's cash burn
  • Consideration of A$30m highlights management’s view of Melodiol’s operating subsidiary value – further value accretive transactions for shareholders are also being explored

Panacea Life Sciences Holdings (https://panacealife.com/), is an OTCQB-listed holding company specialising in the development, manufacturing, research, and distribution of GMP-certified health & wellness and pet care products, chiefly those originating from hemp and CBD.

Panacea’s Extensive Product Suite

Its subsidiary, Panacea Life Sciences, Inc., driven by strong female leadership, prides itself on the research, production, and distribution of the highest-quality nutraceutical, cannabinoid, mushroom, kratom, and other natural, plant-based products. Panacea operates from a sophisticated 51,000 square foot, cGMP- certified facility in Golden, Colorado, ensuring unparalleled quality standards.


Click here for the full ASX Release

This article includes content from Melodial Global Health, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

Melodiol Global Health

Melodiol Global Health Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Melodiol Global Health

Melodiol Global Health


Keep reading...Show less

Cronos Group Announces Expansion of GrowCo to Fuel Global Growth

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, announced an expansion of Cronos Growing Company ("GrowCo"). GrowCo is a leading cannabis cultivation company that Cronos owns 50% of. The investment will be funded by an additional credit facility provided by Cronos and is intended to assist GrowCo's expansion of its purpose-built cannabis facility to address the increased global market demand for high-quality cannabis flower.

Key Highlights of the Investment:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Cannabis plant.

What Would US Cannabis Rescheduling Mean for Stocks and Investors?

The US Drug Enforcement Administration (DEA) has initiated proceedings to reclassify cannabis from a Schedule I substance to a Schedule III substance, marking a significant step towards cannabis reform in the country.

After months of deliberation, the Associated Press reported on April 30 that the DEA would move to reclassify cannabis from Schedule I, a category it currently shares with heroin and methamphetamines, to Schedule III, which is reserved for substances with low potential for dependence and accepted medical use.

The move from the DEA comes almost a year after the Department of Health and Human Services (HHS) suggested that cannabis be reclassified on August 29, 2023. In December 2023, the DEA sent a letter to Congress in which it indicated its intent to review the evidence provided by the HHS. This was followed by months of evaluation and consideration by the DEA, as well as discussions and advocacy for cannabis reform by lawmakers and other stakeholders.

Keep reading...Show less
Cannabis leaves, US flag.

Cannabis Round-Up: US Moves to Reschedule Cannabis, Tilray Brands Seeks US Acquisitions

May saw officials in the Drug Enforcement Administration make the first moves toward cannabis rescheduling.

As anticipation builds, companies are beginning to better position themselves for changing market dynamics, and one Canadian cannabis company is anticipating major acquisition deals to come out of the US.

Meanwhile, a major player in the US market narrowly avoided consequences related to their Nasdaq listing after an expected merger agreement was terminated, and a once luxury cannabis brand out of California became officially delisted after months of financial uncertainty. Keep reading to discover more about these industry-shaping events.

Keep reading...Show less

Trulieve Announces Opening of 200th Dispensary

New Location in Brooksville, Florida opens today with grand opening celebration on June 14 th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Brooksville, Florida marking the Company's 200 th dispensary in the United States .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Announces Litigation Settlement and Acquisition of Ohio Assets

Trulieve adds two medical dispensaries in Beavercreek and Columbus to Ohio footprint

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that it has reached an agreement resolving the active litigation.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Cronos Group Inc. to Speak at Bernstein's 40th Annual Strategic Decisions Conference

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at Bernstein's 40th Annual Strategic Decisions Conference on Thursday, May 30, 2024, at 2:30PM ET.

A live webcast will be available on the Investors section of the Company's website at https://ir.thecronosgroup.com/events-presentations .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Melodiol Global Health

Melodiol Global Health Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×